Rafael (NYSE:RFL) Announces Quarterly Earnings Results

Rafael (NYSE:RFL) released its quarterly earnings data on Thursday. The company reported ($0.08) earnings per share (EPS) for the quarter, FiscalAI reports. The firm had revenue of $0.18 million during the quarter. Rafael had a negative net margin of 2,846.60% and a negative return on equity of 37.27%.

Rafael Trading Down 5.6%

Shares of RFL stock opened at $1.82 on Thursday. The firm has a market capitalization of $94.71 million, a PE ratio of -2.31 and a beta of 0.54. The firm has a fifty day simple moving average of $1.33 and a two-hundred day simple moving average of $1.29. Rafael has a 12 month low of $1.12 and a 12 month high of $2.70.

Hedge Funds Weigh In On Rafael

Several large investors have recently bought and sold shares of RFL. Geode Capital Management LLC lifted its stake in Rafael by 72.9% during the 2nd quarter. Geode Capital Management LLC now owns 451,139 shares of the company’s stock valued at $781,000 after acquiring an additional 190,179 shares in the last quarter. Vanguard Group Inc. grew its holdings in Rafael by 10.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,394,726 shares of the company’s stock valued at $1,897,000 after buying an additional 133,024 shares in the last quarter. Cable Car Capital LP bought a new stake in shares of Rafael during the 2nd quarter valued at about $173,000. Citadel Advisors LLC lifted its position in Rafael by 132.3% in the 3rd quarter. Citadel Advisors LLC now owns 72,584 shares of the company’s stock worth $99,000 after buying an additional 41,335 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its position in Rafael by 59.1% in the 1st quarter. Renaissance Technologies LLC now owns 89,138 shares of the company’s stock worth $111,000 after buying an additional 33,111 shares during the last quarter. 11.30% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of Rafael from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, May 28th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Rafael has a consensus rating of “Sell”.

About Rafael

Rafael Holdings, Inc primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia.